Northern Trust Corp Purchases 668,086 Shares of Hologic, Inc. (NASDAQ:HOLX)

Northern Trust Corp boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,147,420 shares of the medical equipment provider's stock after buying an additional 668,086 shares during the quarter. Northern Trust Corp owned approximately 1.40% of Hologic worth $226,898,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after purchasing an additional 144,838 shares during the period. Victory Capital Management Inc. grew its position in shares of Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after buying an additional 24,358 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after buying an additional 129,035 shares during the last quarter. Invesco Ltd. raised its stake in shares of Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after buying an additional 572,187 shares during the last quarter. Finally, Boston Partners grew its stake in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. William Blair restated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Stephens reiterated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. StockNews.com cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic has a consensus rating of "Hold" and a consensus price target of $79.85.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $0.34 during trading hours on Tuesday, reaching $53.07. 2,348,163 shares of the stock were exchanged, compared to its average volume of 2,774,181. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock's fifty day simple moving average is $60.05 and its 200 day simple moving average is $68.89. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The firm has a market capitalization of $11.91 billion, a price-to-earnings ratio of 16.73, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 earnings per share. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.